DanielOntanedaMDPhD

PubMed

• Choroid plexus volume differentiates MS from its mimics.
  Elle Levit, Zheng Ren, Virgilio Gonzenbach, Christina J Azevedo, Peter A Calabresi, Bruce Ac Cree, Leorah Freeman, Erin E Longbrake, Jiwon Oh, Matthew K Schindler, Nan...> ;Multiple Sclerosis. 2024 Mar 13
• Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.
  Jeremy Chataway, Thomas Williams, Vivien Li, Ruth Ann Marrie, Daniel Ontaneda, Robert J Fox> ;The Lancet. Neurology. 2024 Mar 1
• Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
  Li, Y., Thompson, N., Milinovich, A., Galioto, R., Morgan, A., Abbatemarco, J., Cohen, J., Ontaneda, D., Punia, V., Rae-Grant, A., Kunchok, A.> ;Neurology. 2024 Feb 27
• 2 citations
  Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis: What Is the Future of Multiple Sclerosis Treatment?
  Nicole Bou Rjeily, Ellen M Mowry, Daniel Ontaneda, Alise K Carlson> ;Neurologic Clinics. 2024 Feb 1
• Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
  Nakamura, K., Thoomukuntla, B., Bena, J., Cohen, J., Fox, R., Ontaneda, D.> ;Multiple Sclerosis. 2024 Mar 1
• Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disorders.
  Sanem P Uysal, Yadi Li, Nicolas R Thompson, Alex Milinovich, Justin R Abbatemarco, Jeffrey A Cohen, Devon S Conway, Daniel Ontaneda, John A Morren, Amy Kunchok> ;Annals of Clinical and Translational Neurology. 2024 Mar 1
• Differentiating multiple sclerosis from non-specific white matter changes using a convolutional neural network image classification model.
  Nakamura, K., Amin, M., Ontaneda, D.> ;Multiple Sclerosis and Related Disorders. 2024 Feb 1
• A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
  Daboul, L., O'Donnell, C., Amin, M., Rodrigues, P., Derbyshire, J., Azevedo, C., Bar-Or, A., Caverzasi, E., Calabresi, P., Cree, B., Freeman, L., Henry, R., Longbrake,...> ;Multiple Sclerosis. 2024 Jan 1
• 1 citations
  Re-thinking race and geography in multiple sclerosis.
  Daniel Ontaneda, Lilyana Amezcua> ;Multiple Sclerosis. 2024 Jan 1
• Identification and management of subclinical disease activity in early multiple sclerosis: a review.
  Daniel Ontaneda, Tanuja Chitnis, Kottil Rammohan, Ahmed Z Obeidat> ;Journal of Neurology. 2024 Apr 1
• 1 citations
  Magnetic resonance fingerprinting in multiple sclerosis.
  Daniel Ontaneda, Vikas Gulani, Anagha Deshmane, Amisha Shah, Deepti K Guruprakash, Yun Jiang, Dan Ma, Elizabeth Fisher, Richard A Rudick, Praneeta Raza, Meghan Kilbane...> ;Multiple Sclerosis and Related Disorders. 2023 Nov 1
• Associations Between Cognitive Impairment and Neuroimaging in Patients with Multiple Sclerosis.
  Olivia Wilcox, Moein Amin, Laura Hancock, Kunio Nakamura, John Lace, Daniel Ontaneda, Rachel Galioto> ;Archives of Clinical Neuropsychology. 2024 Feb 19
• 1 citations
  Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
  Kunio Nakamura, Yufan Zheng, Kedar R Mahajan, Jeffrey A Cohen, Robert J Fox, Daniel Ontaneda> ;Multiple Sclerosis. 2023 Sep 1
• Long-term trajectories of ambulatory impairment in multiple sclerosis.
  Douglas D Gunzler, Alessandro S De Nadai, Deborah M Miller, Daniel Ontaneda, Farren Bs Briggs> ;Multiple Sclerosis. 2023 Sep 1
• 1 citations
  The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
  Ebtesam Alshehri, Jeffrey A Cohen, Daniel Ontaneda, Kunio Nakamura, Scott Husak, Thomas E Love, Robert J Fox, Farren Bs Briggs, Devon S Conway> ;Multiple Sclerosis. 2023 Jun 1
• Making Sure Multiple Sclerosis Counts and Is Counted for All-An Update on Multiple Sclerosis Prevalence by Race and Ethnicity in the United States.
  Dalia L Rotstein, Tirisham V Gyang, Daniel Ontaneda> ;JAMA Neurology. 2023 Jul 1
• 4 citations
  The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis.
  Annalisa Morgan, Emma Tallantyre, Daniel Ontaneda> ;Expert Review of Neurotherapeutics. 2023 May 1
• 3 citations
  Incorporating the Central Vein Sign Into the Diagnostic Criteria for Multiple Sclerosis.
  Daniel Ontaneda, Jeffrey A Cohen, Pascal Sati> ;JAMA Neurology. 2023 Jul 1
• 5 citations
  Reproductive issues and multiple sclerosis: 20 questions.
  Alise K Carlson, Daniel Ontaneda, Mary R Rensel, Jeffrey A Cohen, Amy Kunchok> ;Cleveland Clinic Journal of Medicine. 2023 Apr 3
• Pearls & Oy-sters: Hemorrhagic Myelitis Following SARS-CoV-2 Infection.
  Karlo Toljan, Ahmad Mahadeen, Moein Amin, Mary Rensel, Stephen E Jones, Daniel Ontaneda, Amy C Kunchok> ;Neurology. 2023 Aug 8
• 1 citations
  "It's on the tip of my tongue!" exploring confrontation naming difficulties in patients with multiple sclerosis.
  Tiffany Grezmak, John W Lace, Kunio Nakamura, Daniel Ontaneda, Rachel Galioto> ;Multiple Sclerosis and Related Disorders. 2023 Mar 1
• 9 citations
  Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice: A Scoping Review.
  Shreya Louis, Alise K Carlson, Abhilash Suresh, Joshua Rim, MaryAnn Mays, Daniel Ontaneda, Andrew Dhawan> ;Neurology. 2023 Mar 7
• MRI Features of Anti-Ma1/Ma2 Paraneoplastic Neurologic Syndrome.
  Amy C Kunchok, Daniel Ontaneda, Jonathan Lee, Alexander Rae-Grant, Nancy Foldvary-Schaefer, Jeffrey A Cohen, Stephen E Jones> ;Neurology. 2022 Nov 15
• 1 citations
  Benefits of early treatment with natalizumab: a real-world study.
  Daniel Ontaneda, Ellen M Mowry, Scott D Newsome, Robert T Naismith, Jacqueline Nicholas, Elizabeth Fisher, Carl de Moor, Justin Bohn, Pei-Ran Ho, Al Sandrock, Richard ...> ;Multiple Sclerosis and Related Disorders. 2022 Dec 1
• 1 citations
  Gadolinium-based contrast agent exposures and physical and cognitive disability in multiple sclerosis.
  Kunio Nakamura, Marisa P McGinley, Stephen E Jones, Mark J Lowe, Jeffrey A Cohen, Paul M Ruggieri, Daniel Ontaneda> ;Journal of Neuroimaging. 2023 Jan 1
• Join now to see all

Journal Articles

• Keep the Worms in the Mud  
  Daniel Ontaneda, MD, JAMA Neurology
• Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives  
  Ontaneda D, Fox RJ, Chataway J, Lancet Neurology, 1/1/2015
• Experience with Fingolimod in clinical practice  
  Hersh C, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, Ontaneda D, Int J Neurosci, 1/29/2014
• Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study  
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe MJ, Phillips MD, Fox RJ, Journal of Neuroimaging, 1/1/2014
• Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?  
  Ontaneda D, Fox RJ, Int J Neurosci, 1/1/2014
• Diffusion Tensor Imaging before, during and after progressive multifocal leukoencephalopathy  
  Ontaneda D, Sakaie K, Lin J, Lowe MJ, Phillips MD, Fox RJ, European Journal of Neurology, 1/1/2014
• Sensitivity to Volatile Anesthetics in Patients with Dementia: A Case-control Analysis  
  Perez S, Guebe M, Ontaneda D, Dalton J, Kurz A, Sessler D, Canadian Journal of Anesthesia, 1/1/2014
• Risk Stratification and mitigation in multiple sclerosis  
  Ontaneda D, Cohn S, Fox, R, Multiple Sclerosis and Related Disorders Mult Scler Relat Disord, 1/1/2014
• Multiple sclerosis treatment: risk mitigation  
  Ontaneda D, Fox RJ, Continuum (Minneap Minn), 1/1/2013
• The benefits and risks of alemtuzumab in multiple sclerosis  
  Ontaneda D, Cohen JA, Expert Rev Clin Pharmacol, 1/1/2013
• Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures  
  Ontaneda D, Larocca N, Coetzee T, Rudick R, On behalf of the NMSS MSFC Task Force listed in Appendix, Mult Scler J, 1/1/2012
• Benefits versus risks of latest therapies in multiple sclerosis: a perspective review  
  Ontaneda D, Di Capua D, Therapeutic Advances in Drug Safety, 1/1/2012
• Early tolerability and safety of fingolimod in clinical practice  
  Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen J, Bermel R, J Neurol Sci, 1/1/2012
• EDSS Improvement: Recovery of Function or Noise?  
  Ontaneda D, Cohen JA, Mult Scler J, 1/1/2012
• Relapsing-Remitting Multiple Sclerosis -Current Treatment Options and Perspectives for the Future  
  Ontaneda Daniel, Rae-Grant Alex, European Neurological Review, 1/1/2010
• Race/ethnic differences in AD survival in us Alzheimer's disease centers (Author reply)  
  Ontaneda D, Neurology, 1/1/2009
• Join now to see all

Books/Book Chapters

• Multiple Sclerosis: A Guide to Pharmacologic Treatment. 
  Ontaneda DSEEd edizioni scientifiche, Turin, Italy2013
• The 5 Minute Neurology Consult. 
  Chapter: Neuromyelitis Optica. 
  Ontaneda D, Rae-Grant AD Neuromyelitis OpticaEditors: Lyne DJ, Newton HB, Rae-Grant AD.Lippincott Williams & Wilkins, Philadelphia, PAEdition 2nd,
• Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation. 
  Chapter: Emerging Therapies in MS. 
  Ontaneda D, Fox REditors: Rae-Grant AD, Fox RJ, Bethoux F.Demos Medical Publishing

Abstracts/Posters

• Early tolerability of dimethyl fumarate for treatment of multiple sclerosis.
  Cohn S, Bermel R, Fox R, Cohen J, Ontaneda D, American Academy of Neurology Annual Meeting, Philadelphia, PA, 1/1/2014
• Pilot clinical trial of vitamin d supplementation in secondary progressive multiple sclerosis.
  Ontaneda D, Cohen JA, Clinical and Translational Science 2014, Translational Science 2013 Meeting, Washington, DC, 1/1/2014
• Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in multiple sclerosis.
  Cohn S, Bermel R, Hara C, Hersh C, Fox RJ, Cohen J, Ontaneda D, Americas/European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Boston, MA, 1/1/2014
• Vitamin D levels are associated with low cortical thickness in secondary progressive MS.
  Ontaneda D, Planchon S, Cohen J, Fisher E, Americas/European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Boston, MA, 1/1/2014
• Tolerability and Efficacy of Fingolimod in Clinical Practice (P01.183).
  Hersh C, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, Ontaneda D, Neurology, American Academy of Neurology Annual Meeting, San Diego, CA, 1/1/2013
• Region of interest versus tractography analysis of the corticospinal tract using diffusion tensor imaging (P112).
  Ontaneda D, Atthe B, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, Clinical and Translational Science, Translational Science 2013 Meeting, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Washington, DC, 2013; Copenhagen, Denmark, 2013, 1/1/2013
• Early Tolerability and Safety of Fingolimod in Clinical Practice (P04.130).
  Ontaneda D, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Cardiovascular Effects and Safety of Fingolimod in Clinical Practice (P04.138).
  Ontaneda D, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, Neurology, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Four-Year Evolution of Brain Tissue Integrity Using Diffusion Tensor Imaging in Multiple Sclerosis (P03.037).
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, Neurology, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Four-year evolution of multiple sclerosis lesions using diffusion tensor imaging (1419).
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Lyon, France, 1/1/2012
• Diffusion tensor imaging predicts development of natalizumab-associated progressive multifocal leukoencephalopathy (1422).
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Lyon, France, 1/1/2012
• Anatomical Specificity of Diffusion Tensor Imaging and The Timed 25 Foot Walk (S46).
  Ontaneda D, Sakaie K, Lin J, Wang, X, Lowe MJ, Phillips MD, Fox RJ, Int J MS Care, Consortium of Multiple Sclerosis Centers Annual Meeting, Montreal, Canada, 1/1/2011
• Depression and disease-modifying agents in multiple sclerosis: a propensity matched comparison (P709).
  Ontaneda D, Cohen JA, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Amsterdam, The Netherlands, 1/1/2011
• Cryptococcosis of the CNS Presenting with Disseminated White Matter Lesions.
  Ontaneda D, Shook, S, American Society of Neuroimaging Meeting, San Francisco, CA, 1/1/2010
• Is NMO a Paraneoplastic Marker?
  Ontaneda D, Saupe W, Fox RJ, American Academy of Neurology Annual Meeting, Toronto, Canada, 1/1/2010
• Identifying the Start of Multiple Sclerosis Inflammation: A Serial DTI Study (IN7-2.010).
  Ontaneda D, Sakaie K, Lin J, Wang, X, Lowe MJ, Phillips MD, Fox RJ, American Academy of Neurology Annual Meeting, Toronto, Canada, 1/1/2010
• Transient locked in syndrome and basilar occlusion (P07).
  Ontaneda D, Shook, S, Journal of Neuroimaging, American Society of Neuroimaging Meeting, Orlando, FL, 1/1/2009
• Hand muscle atrophy in multiple sclerosis (P08).
  Ontaneda D, Shook, S, Journal of Neuroimaging, American Society of Neuroimaging Meeting, Tucson, AZ, 1/1/2008
• Factors related to the absence or discontinuation of disease modifying therapy in an Academic MS Center (S59).
  Ontaneda D, Ordonez L, Skromne E, Hutton G, Rivera V, Int J MS Care; Consortium of Multiple Sclerosis Centers Annual Meeting, Scottsdale, AZ, 1/1/2006
• Join now to see all

Lectures

• Where Are We With Vitamin D, and What's All the Fuss? 
  Cleveland, OH - 1/27/2014
• Advances in secondary progressive multiple sclerosis. 
  Monterrey, Mexico - 1/19/2014
• Current and Future Therapies in Multiple Sclerosis. 
  Washington, DC - 1/1/2014
• Risk of Therapies in Multiple Sclerosis. 
  Washington, DC - 1/1/2014
• Mellen Center Update on Multiple Sclerosis (MS) 
  Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Cleveland, Ohio - 6/21/2013
• Clinicians rate risk of disabling MS less than risk of effective treatment. 
  Vienna, Austria - 1/23/2013
• Multiple Sclerosis Treatment: from conventional immunomodulatory drugs to new imunossupressive drugs, and patients risk management. 
  Sao Paulo, Brazil - 1/23/2013
• Risk Stratification in Using Disease Modifying Therapy in 2013. 
  Cleveland, OH - 1/21/2013
• Update on Multiple Sclerosis. 
  Villahermosa, Mexico - 1/14/2013
• Treatment of Stoke Complications. 
  Villahermosa, Mexico - 1/13/2013
• What Does Progressive MS Mean? What's Hot in MS Program. 
  Cleveland, OH - 1/3/2012
• An Update on Oral Therapies in Multiple Sclerosis. 
  1/2/2012
• Identifying the Start of the Multiple Sclerosis Lesion: A review of Pre-lesional Data. 
  1/28/2010
• Cheer-leading Swinging and Swimming Interrupted. 
  1/15/2009
• A Toddler with Twitches. 
  1/7/2007
• Join now to see all